Literature DB >> 15745111

Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry.

Rajendra P Maskey1, Elisabeth Helmke, Oliver Kayser, Heinz H Fiebig, Armin Maier, Andreas Busche, Hartmut Laatsch.   

Abstract

The ethyl acetate extract from the Streptomyces sp. isolate B8652 delivered the trioxacarcins A to approximately C (2a to approximately 2c) and additionally three new derivatives designated as trioxacarcins D to approximately F (2d to approximately 2f). All trioxacarcins showed high anti-bacterial and some of them high anti-tumor and anti-malaria activity. The structures of the new antibiotics were derived from mass, 1D and 2D NMR spectra and confirmed by comparison of the NMR data with those of known derivatives. The absolute configuration of the trioxacarcins is deduced from the X-ray analysis of gutingimycin (2g) and from the known stereochemistry of the L-trioxacarcinoses A and B.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15745111     DOI: 10.7164/antibiotics.57.771

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  31 in total

1.  Larvicidal activity of isolated compound 5-(2,4-dimethylbenzyl) pyrrolidin-2-one from marine Streptomyces VITSVK5 sp. against Rhipicephalus (Boophilus) microplus, Anopheles stephensi, and Culex tritaeniorhynchus.

Authors:  Kumar Saurav; Govindasamy Rajakumar; Krishnan Kannabiran; Abdul Abdul Rahuman; Kanayairam Velayutham; Gandhi Elango; Chinnaperumal Kamaraj; Abdul Abduz Zahir
Journal:  Parasitol Res       Date:  2011-10-19       Impact factor: 2.289

Review 2.  Antiplasmodial marine natural products in the perspective of current chemotherapy and prevention of malaria: a review.

Authors:  Dominique Laurent; Francesco Pietra
Journal:  Mar Biotechnol (NY)       Date:  2006-03-30       Impact factor: 3.619

Review 3.  Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2007-02-09       Impact factor: 3.228

4.  The SARP Family Regulator Txn9 and Two-Component Response Regulator Txn11 are Key Activators for Trioxacarcin Biosynthesis in Streptomyces bottropensis.

Authors:  Kui Yang; Li-Hua Qi; Mei Zhang; Xian-Feng Hou; Hai-Xue Pan; Gong-Li Tang; Wei Wang; Hua Yuan
Journal:  Curr Microbiol       Date:  2015-07-16       Impact factor: 2.188

Review 5.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

6.  Bioactive compounds from marine actinomycetes.

Authors:  Renu Solanki; Monisha Khanna; Rup Lal
Journal:  Indian J Microbiol       Date:  2009-01-08       Impact factor: 2.461

7.  Research on marine actinobacteria in India.

Authors:  K Sivakumar; Maloy Kumar Sahu; T Thangaradjou; L Kannan
Journal:  Indian J Microbiol       Date:  2007-10-04       Impact factor: 2.461

8.  In vivo antimalarial activity of the endophytic actinobacteria, Streptomyces SUK 10.

Authors:  Mohd Shukri Baba; Noraziah Mohamad Zin; Zainal Abidin Abu Hassan; Jalifah Latip; Florence Pethick; Iain S Hunter; RuAngelie Edrada-Ebel; Paul R Herron
Journal:  J Microbiol       Date:  2015-12-02       Impact factor: 3.422

Review 9.  Antitumor compounds from marine actinomycetes.

Authors:  Carlos Olano; Carmen Méndez; José A Salas
Journal:  Mar Drugs       Date:  2009-06-11       Impact factor: 5.118

Review 10.  Immense essence of excellence: marine microbial bioactive compounds.

Authors:  Ira Bhatnagar; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-10-15       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.